Comprehensive Modeling and Discovery of Mebendazole as a Novel TRAF2- and NCK-interacting Kinase Inhibitor
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
TRAF2- and NCK-interacting kinase (TNIK) represents one of the crucial targets for Wnt-activated colorectal cancer. In this study, we curated two datasets and conducted a comprehensive modeling study to explore novel TNIK inhibitors with desirable biopharmaceutical properties. With Dataset I, we derived Comparative Molecular Similarity Indices Analysis (CoMSIA) and variable-selection k-nearest neighbor models, from which 3D-molecular fields and 2D-descriptors critical for the TNIK inhibitor activity were revealed. Based on Dataset II, predictive CoMSIA-SIMCA (Soft Independent Modelling by Class Analogy) models were obtained and employed to screen 1,448 FDA-approved small molecule drugs. Upon experimental evaluations, we discovered that mebendazole, an approved anthelmintic drug, could selectively inhibit TNIK kinase activity with a dissociation constant K d = ~1 μM. The subsequent CoMSIA and kNN analyses indicated that mebendazole bears the favorable molecular features that are needed to bind and inhibit TNIK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Wnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595
Rational selection of training and test sets for the development of validated QSAR models
Golbraikh, A., Shen, M., Xiao, Z., Xiao, Y.-D., Lee, K.-H., & Tropsha, A. (2003) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1025386326946 · Cited by 712
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism · doi:10.2174/138920009788897975 · Cited by 630
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Bai, R.-Y., Staedtke, V., Aprhys, C. M., Gallia, G. L., & Riggins, G. J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor077 · Cited by 201
Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2159 · Cited by 152
Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice
Martarelli, D., Pompei, P., Baldi, C., & Mazzoni, G. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0538-0 · Cited by 101
Cited by
Katoh, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4129 · Cited by 465
Guerini, A. E., Triggiani, L., Maddalo, M., Bonù, M. L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., Pasinetti, N., et al. (2019) · Cancers · doi:10.3390/cancers11091284 · Cited by 146
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55
Metadata
- Authors
- Tan, Z., Chen, L., & Zhang, S.
- Venue
- Scientific Reports
- Published
- 2016-09-21
- Volume
- 6
- Issue
- 1
- Pages
- 33534-33534
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2521080956
- Cited by
- 39
- References
- 7
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.